ALEC Overview

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.

Wall Street analysts forecast ALEC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALEC is2.10 USD with a low forecast of 0.90 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Alector Inc revenue for the last quarter amounts to 3.26M USD, decreased -78.75 % YoY.

Alector Inc. EPS for the last quarter amounts to -0.34 USD, decreased -20.93 % YoY.

Alector Inc (ALEC) has 238 emplpoyees as of February 09 2026.

Today ALEC has the market capitalization of 213.94M USD.